Following a nod from the FDA, Siemens Healthineers is now gearing up for the release of its MAMMOMAT Revelation, a premium mammography platform designed to improve diagnostic confidence and earlier lesion detection in patients with dense breast tissue.
Equipped with HD Breast Tomosynthesis and InSpect integrated specimen imaging, the solution enables one-click targeting of suspicious areas and the ability to assess biopsy samples in real time on the same system, thereby improving patient experience and expanding the capabilities of precision medicine.
“Once specimens are acquired during a biopsy, the technologist has to leave the patient to find an open system to X-ray the specimen, or rely on a standalone specimen imager that may be located in another area,” Pam Cumming, senior director of product marketing/womens health, Siemens Healthineers North America, told HCB News. “This capability is actually integrated right into the system so the technologist never has to leave the patient’s side or release her from compression, which might require additional dose to re-target. She can always be with her and keep her anxiety level down, minimize time in compression, and work more efficiently.”
Nearly half of women undergoing mammograms in the U.S. have dense breast tissue, making it challenging for conventional systems to detect lesions. MAMMOMAT Revelation offers automated breast density measurement during exams for personalized risk stratification and more personalized care.
The addition of HD Breast Tomosynthesis provides the solution with the widest image acquisition angle available at 50 degrees.
This creates a high depth resolution for better separation of overlapping breast tissue and better 3-D visualization of abnormalities in breast tissue, qualities that enable the technologist to use one-click targeting with +/- 1mm accuracy to pinpoint the location of these abnormalities.
Technologists can also scan biopsies without leaving the room by using the solution’s InSpect integrated specimen imaging tool. The biopsy specimens are placed inside a small plastic box that slides onto the biopsy device, and the tube head automatically collimates to this area on the detector. The specimen images appear on technologist’s acquisition workstation within seconds.
This allows the technologist to remain with the patient to provide support and reduce feelings of anxiety.
Those with inconclusive cases have the option of undergoing MAMMOMAT Revelation’s titanium contrast-enhanced mammography, a cost-effective alternative to MR imaging, thereby reducing scheduling conflicts and offering reassurance to the patient.
